This results in robust anti-tumour responses across both age groups: in young mice, strong CD8+ T-cell cytotoxicity facilitates tumour clearance, whereas in aged mice, the response shifts to cytolytic CD4+ helper T-cell activity, directly killing tumour cells and enhancing the effectiveness of immunotherapy [80]. Here, CD8A is linked to neoplasm.